Alaunos Therapeutics and its Subsidiary Velaris Therapeutics to Participate in Upcoming November Investor Conferences

Nov 02, 2026

FORT LAUDERDALE, Fla., November 2, 2026 – Alaunos Therapeutics, Inc. (NASDAQ: TCRT), a biotechnology company developing potentially best-in-class therapies for pulmonary arterial hypertension (PAH) and secondary pulmonary hypertension, today announced the participation by representatives of its subsidiary, Velaris Therapeutics, at key Investor conferences taking place in November 2026:

- **Stifel 2026 Healthcare Conference** *(November 10-12)*
  Date: Wednesday, November 11, 2026
  Fireside Time: 8:00 a.m. ET
  New York, NY

- **UBS Global Biopharma Conference 2026** *(November 16-17)*
  Date: Tuesday, November 17, 2026
  Fireside Time: 10:00 a.m. GMT
  London

- **Jefferies London Healthcare Conference 2026** *(November 16-19)*
  Date: Wednesday, November 18, 2026
  Fireside Time: 4:30 p.m. GMT
  London

Live webcasts of the presentations will be available under the “Events and Presentations” tab in the Investors section of the Alaunos website at https://ir.alaunos.com/events-presentations. An archived replay will be accessible for 30 days following the event.

About Alaunos Therapeutics

Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics. The Company’s obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology.

About Velaris Therapeutics

Velaris Therapeutics is a biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. Velaris is developing ActRII-Fc ligand traps and complementary biologics designed to maximize the potential of these classes of therapies. VLR199, with broad ligand activity, is designed to replicate clinically validated pharmacology but improving where it is not fully optimized. VLR247 and VLR258, featuring distinct ActRII extracellular domains, are designed to spare BMP-9 and BMP-10 and lower risk for hematologic adverse events. The pipeline also features VLR360, an anti-PDGF-B monoclonal antibody, which offers a complementary approach that alone or in combination with the ActRII-Fcs is designed to address the signaling imbalances that drive remodeling of the pulmonary vasculature. Velaris’ assets were discovered by Paragon Labs. Velaris is based in Waltham, MA. For more information, visit velaristx.com.

Media Contact
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com